IGF1 and type 2 diabetes mellitus: Recombinant IGF-I significantly lowered blood glucose and increased insulin sensitivity in a small trial of subjects with type 2 diabetes, when administered subcutaneously for 6 weeks at supraphysiological doses (100 μg/kg twice daily); however, such treatment was associated with several adverse effects which limit translation to the clinic [25].